Merck And Co Inc (MRK) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Merck and Co Inc   (NYSE: MRK)
 

Merck And Co Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRK Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 5.07 % 12.22 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 1.97 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 4.64 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 1.22 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 6.26 % 7.41 % 8.65 % 10.59 %


MRK's Growth Comparisons in II. Quarter 2026




Comparing 5.07% year on year top-line growth in the second quarter 2026, Merck And Co Inc grew on the lower pace than the 12.22% rise in the Major Pharmaceutical Preparations industry and 8.91% Revenue growth in the Healthcare sector. Comparing the second quarter, sales Merck And Co Inc was trailing overall market not just Major Pharmaceutical Preparations industry.

Comparing the company's Revenue to the first quarter results, sales were higher by 1.97% . On the yearly basis, average annual sales growth for Merck And Co Inc is 6.26%, while S & P 500's including only Businesses with the second quarter 2026 earnings, average annual sales growth is 10.59% over the past five years.

MRK Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
U S
7.14 %
-
Non-US
4.59 %
-
Pharmaceutical
5.21 %
-
Animal Health
12.78 %
-
U S Pharmaceutical
7.38 %
-
U S Animal Health
3.39 %
-
Non-US Pharmaceutical
2.21 %
-
Non-US Animal Health
17.13 %
-
Keytruda Pharmaceutical
9.73 %
-
Keytruda U S Pharmaceutical
6.75 %
-
Keytruda Non-US Pharmaceutical
14.15 %
-
Keytruda Qlex Pharmaceutical
-
-
Keytruda Qlex U S Pharmaceutical
-
-
Keytruda Qlex Non-US Pharmaceutical
-
-
Alliance revenue - Lynparza Pharmaceutical
9.29 %
-
Alliance revenue - Lynparza U S Pharmaceutical
2.76 %
-
Alliance revenue - Lynparza Non-US Pharmaceutical
14.29 %
-
Alliance revenue - Lenvima Pharmaceutical
-0.78 %
-
Alliance revenue - Lenvima U S Pharmaceutical
-5.38 %
-
Alliance revenue - Lenvima Non-US Pharmaceutical
11.11 %
-
Welireg Pharmaceutical
45.26 %
-
Welireg U S Pharmaceutical
23.58 %
-
Welireg Non-US Pharmaceutical
213.33 %
-
Alliance Revenue - Reblozyl Pharmaceutical
24.37 %
-
Alliance Revenue - Reblozyl U S Pharmaceutical
26.73 %
-
Alliance Revenue - Reblozyl Non-US Pharmaceutical
11.11 %
-
Gardasil Gardasil 9 Pharmaceutical
-19.44 %
-
Gardasil Gardasil 9 U S Pharmaceutical
-9.51 %
-
Gardasil Gardasil 9 Non-US Pharmaceutical
-25.95 %
-
ProQuad M-M-R II Varivax Pharmaceutical
-0.19 %
-
ProQuad M-M-R II Varivax U S Pharmaceutical
-3.31 %
-
ProQuad M-M-R II Varivax Non-US Pharmaceutical
11.21 %
-
RotaTeq Pharmaceutical
-9.65 %
-
RotaTeq U S Pharmaceutical
0.61 %
-
RotaTeq Non-US Pharmaceutical
-34.38 %
-
Vaxneuvance Pharmaceutical
-12.17 %
-
Vaxneuvance U S Pharmaceutical
-11.51 %
-
Vaxneuvance Non-US Pharmaceutical
-15.22 %
-
Capvaxive Pharmaceutical
32.71 %
-
Capvaxive U S Pharmaceutical
11.32 %
-
Capvaxive Non-US Pharmaceutical
2200 %
-
Winrevair Pharmaceutical
87.5 %
-
Winrevair U S Pharmaceutical
77.99 %
-
Winrevair Non-US Pharmaceutical
300 %
-
Ohtuvayre Pharmaceutical
-
-
Ohtuvayre U S Pharmaceutical
-
-
Alliance revenue - Adempas Verquvo Pharmaceutical
2.83 %
-
Alliance revenue - Adempas Verquvo U S Pharmaceutical
12.37 %
-
Adempas Pharmaceutical
14.71 %
-
Adempas Non-US Pharmaceutical
14.71 %
-
Bridion Pharmaceutical
7.03 %
-
Bridion U S Pharmaceutical
12.96 %
-
Bridion Non-US Pharmaceutical
-28.57 %
-
Prevymis Pharmaceutical
30.77 %
-
Prevymis U S Pharmaceutical
32.35 %
-
Prevymis Non-US Pharmaceutical
30.19 %
-
Zerbaxa Pharmaceutical
17.14 %
-
Zerbaxa U S Pharmaceutical
23.81 %
-
Zerbaxa Non-US Pharmaceutical
7.14 %
-
Delstrigo Pharmaceutical
11.94 %
-
Delstrigo U S Pharmaceutical
-33.33 %
-
Delstrigo Non-US Pharmaceutical
25 %
-
Isentress Isentress HD Pharmaceutical
-34.44 %
-
Isentress Isentress HD U S Pharmaceutical
-31.37 %
-
Isentress Isentress HD Non-US Pharmaceutical
-38.46 %
-
Dificid Pharmaceutical
-59.04 %
-
Dificid U S Pharmaceutical
-66.67 %
-
Dificid Non-US Pharmaceutical
-9.09 %
-
Lagevrio Pharmaceutical
-72.55 %
-
Lagevrio U S Pharmaceutical
-54.29 %
-
Lagevrio Non-US Pharmaceutical
-82.09 %
-
Januvia Pharmaceutical
-33.15 %
-
Januvia U S Pharmaceutical
-26.74 %
-
Januvia Non-US Pharmaceutical
-43.14 %
-
Janumet Pharmaceutical
-16.19 %
-
Janumet U S Pharmaceutical
4.62 %
-
Janumet Non-US Pharmaceutical
-23.63 %
-
Other pharmaceutical Pharmaceutical
-10.4 %
-
Other pharmaceutical U S Pharmaceutical
-26.87 %
-
Other pharmaceutical Non-US Pharmaceutical
-4.55 %
-
Livestock Animal Health
15.15 %
-
Livestock U S Animal Health
8.76 %
-
Livestock Non-US Animal Health
16.85 %
-
Companion Animal Animal Health
9.49 %
-
Companion Animal U S Animal Health
0 %
-
Companion Animal Non-US Animal Health
17.7 %
-
Alliance revenue - Koselugo Pharmaceutical
265.91 %
-
Corporate Non-Segment
-51.82 %
-
Corporate Non-U S
43.01 %
-
Corporate Non-Non-US
-93.81 %
-
United States
7.53 %
-
Europe Middle East and Africa
12.51 %
-
Latin America
10.35 %
-
Asia Pacific other than China and Japan
7.11 %
-
Japan
-17.04 %
-
China
-44.44 %
-
Other
-3.14 %
-
Total profits
6 %
-
Total profits Pharma- ceutical
5.21 %
-
Total profits Animal Health
12.78 %
-
Other profits
-51.82 %
-
Total
4.87 %
-


Growth Rates of MRK's Income in the second quarter 2026


MRK Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -8.88 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) -63.52 % 30.63 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) -41.76 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change 21.83 % 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -34.9 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) -80.69 % 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) -64.52 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 20.86 % -0.55 % 0.17 % -28.52 %

MRK Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -35.09 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) - 2.87 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) -80.69 % 5.21 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) -64.52 % -10.17 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth 20.86 % 14.55 % 9.21 % 22.96 %

MRK's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -40.27 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - -7.72 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) -80.92 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) -64.97 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 32.46 % -10.79 % 0.17 % -28.52 %



MRK EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -40.45 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) - -2.53 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) -64.97 % - - 4.93 %
EPS Net 5 Year Avg. Change 22.37 % 14.55 % 9.21 % 22.96 %



Merck And Co Inc reported bottom-line of $ -0.54 in the second quarter, compare to $ 1.76 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -40.45%, while Healthcare sector decreased by -26.26%, and overall market improved by 90.69%.

Comparing company's EPS to the first quarter results, income per share were higher by 1.97% . On the yearly basis, average annual income per share growth for Merck And Co Inc is 22.37%, while S & P 500's including only the businesses with the second quarter 2026 Results, average annual income per share growth is 22.96% over the past five years.

MRK Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 77.03 % 25.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) 52.96 % -42.37 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 9.11 % 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 13.8 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change 17.29 % 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 16.88 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) -9.89 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 2.41 % 16.65 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 3.42 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -2.57 % 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.